Tirzepatide SURPASS Trials: Dual GIP/GLP-1 Receptor Agonism Delivers Superior Glycemic Control and Weight Loss

Background

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes and obesity. Unlike single-incretin therapies such as semaglutide, tirzepatide simultaneously activates both the GIP and GLP-1 receptors, a mechanism hypothesized to produce additive or synergistic effects on insulin secretion, appetite suppression, and energy expenditure. The SURPASS clinical trial program — comprising five pivotal phase 3 studies (SURPASS-1 through SURPASS-5) — evaluated tirzepatide across a range of type 2 diabetes populations over 40 to 52 weeks.

Methods

The SURPASS program enrolled thousands of adults with type 2 diabetes across varying treatment backgrounds. SURPASS-1 examined tirzepatide as monotherapy versus placebo in 478 treatment-naive patients. SURPASS-2, published in the New England Journal of Medicine, directly compared tirzepatide (5 mg, 10 mg, and 15 mg weekly) against semaglutide 1 mg weekly in 1,879 patients on background metformin. SURPASS-3 compared tirzepatide against insulin degludec, while SURPASS-4 and SURPASS-5 evaluated tirzepatide against insulin glargine and as an add-on to basal insulin, respectively. The primary endpoint across trials was change in HbA1c from baseline, with body weight change as a key secondary endpoint.

Key Findings

Across all five SURPASS trials, tirzepatide demonstrated HbA1c reductions of 1.9% to 2.6% from baseline over 40 to 52 weeks. In SURPASS-1, the 15 mg dose achieved a mean HbA1c reduction of 2.07%, with 52% of patients reaching normoglycemia (HbA1c below 5.7%). Body weight reductions ranged from 7.0 to 9.5 kg, and 31% to 47% of patients achieved at least 10% weight loss.

In the head-to-head SURPASS-2 trial, tirzepatide at all three doses was noninferior and superior to semaglutide 1 mg for HbA1c reduction. The 15 mg dose reduced HbA1c by 2.30% compared to 1.86% with semaglutide. Weight loss was also significantly greater with tirzepatide, with the highest dose producing approximately 12.4 kg of weight loss versus 6.2 kg with semaglutide.

Post hoc analyses across SURPASS-1 through SURPASS-5 demonstrated that 43% to 82% of tirzepatide-treated patients achieved a composite endpoint of HbA1c below 7.0% with at least 5% weight loss and no hypoglycemia, compared to 4% to 5% with placebo. Additional analyses showed significant reductions in systolic blood pressure and metabolic syndrome prevalence.

Implications

The SURPASS data suggest that dual GIP/GLP-1 receptor agonism may represent a meaningful advance over single-incretin approaches for type 2 diabetes management. The combination of robust glycemic control, substantial weight loss, and favorable cardiometabolic effects positions tirzepatide as a potential cornerstone therapy. The ongoing SURMOUNT-MMO cardiovascular outcomes trial is expected to clarify the long-term cardiovascular benefits of tirzepatide in patients without diabetes.

Limitations

The SURPASS trials were industry-sponsored, and the 40- to 52-week durations, while substantial, do not fully address long-term safety and durability of response. Gastrointestinal adverse events — nausea, diarrhea, and vomiting — were the most common side effects and led to discontinuation in a small percentage of participants. The SURPASS-2 comparison used semaglutide 1 mg, which is below the 2.4 mg dose approved for obesity, potentially limiting the generalizability of head-to-head weight loss comparisons.